Biologics and Sublingual Immunotherapy
ConditionAsthma, Allergic
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMedical University of Silesia
About this trial
Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.
Eligibility criteria
Qualifiers
A total IgE between 30-700 IU/mL
Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;
FEV1 >70% at baseline;
Positive skin prick test results for D. pteronyssinus, D. farinae
Disqualifiers
Sensitisation to other allergens with clinical signs not related to HDM
Uncontrolled asthma,
Other serious diseases or chronic unstable diseases
Allergen immunotherapy during the past 5 years
Trial design
Treatments tested in this trial
- omalizumab
Treatment groups
150 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Medical University of Silesia
Lead sponsor
Centrum Medyczne Andrzej Bożek
Collaborator
Source ClinicalTrials.gov